相关实验视频
Updated: Jun 22, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
在患有炎症性肠病的患者中,延迟启动生物治疗的相关因素
Alexander Abadir1, Angela Troia2, Hyder Said1
1Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA, 02215, USA.
对于炎症性肠病 (IBD) 开始生物治疗的延迟是显著的. 种族,治疗距离和保险问题等因素导致这些延迟,影响患者的护理.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 及时启动生物疗法对于管理炎症性肠病 (IBD) 至关重要.
- 临床,社会和财务因素可能会阻碍对生物药物的门诊启动.
- 了解这些延迟是改善患者获得先进疗法的关键.
研究的目的:
- 评估IBD患者先进治疗开始延迟的持续时间.
- 确定导致生物治疗启动延迟的具体因素.
主要方法:
- 一项多中心的回顾性研究分析了411名开始生物治疗的IBD患者.
- 数据是在2019年3月至2020年9月期间收集的.
- 单变量和多变量线性回归确定了与治疗开始延迟相关的变量,定义为从处方到第一剂量的几天.
主要成果:
- 在所有药物中,生物启动的中位延迟为20天.
- 与较长的延误相关的关键因素包括自我识别为黑人,离治疗设施更远的距离,以及最初缺乏保险批准.
- 具体的药物延迟有所不同,因弗利西马布在19天,阿达利穆马布在10天,维多利祖马布/乌斯特基努马布在21天.
结论:
- 在启动IBD生物治疗时存在显著的延迟.
- 患者种族 (黑人),治疗中心的地理距离和保险覆盖问题是及时治疗的关键障碍.
- 解决这些差异对于公平获得IBD生物药物至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

